KMT2A and acute myeloid leukemia: Our ex vivo and in vivo results with NUP98-r AML models suggest that samples expressing mutated WT1 or FLT3-ITD respond favorably to MLL–Menin inhibition, indicating that these mutations do not necessarily lead to treatment resistance.